CO6501157A2 - Sales de adición de trometamina con derivados de ácido azabifenilaminobenzoico como inhibidores de dhodh - Google Patents

Sales de adición de trometamina con derivados de ácido azabifenilaminobenzoico como inhibidores de dhodh

Info

Publication number
CO6501157A2
CO6501157A2 CO11112331A CO11112331A CO6501157A2 CO 6501157 A2 CO6501157 A2 CO 6501157A2 CO 11112331 A CO11112331 A CO 11112331A CO 11112331 A CO11112331 A CO 11112331A CO 6501157 A2 CO6501157 A2 CO 6501157A2
Authority
CO
Colombia
Prior art keywords
addition salts
azabifenylaminobenzoic
trometamine
acid derivatives
dhodh inhibitors
Prior art date
Application number
CO11112331A
Other languages
English (en)
Inventor
Gonzalez Nuria Garcia
Carrera Francese Carrera
Jane Montserrat Julia
Laurent Debethune
Masia Xavier Serra
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40671396&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6501157(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of CO6501157A2 publication Critical patent/CO6501157A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Abstract

La presente invención se refiere a nuevas sales de adición cristalinas de (i) trometamina con (ii) un derivado de ácido azabifenilaminobenzoico de fórmula (I)en la queR1 se selecciona del grupo que consiste en alquilo C1-C4, cicloalquilo C3-C6 y CF3, G1 se selecciona de átomos de nitrógeno y grupos CH, C(CH3) y C(CF3), yG2 representa un grupo fenilo opcionalmente sustituido con uno o dos sustituyentes seleccionados de cloro, fluoro, metoxi, etoxi, isopropoxi, trifluorometoxi, CF3, y CONR7R8, en donde R7 es hidrógeno y R8 es ciclopropilo o R7 y R8 junto con el átomo de nitrógeno al que están unidos forman un grupo de fórmulaDonde n es 1y sus solvatos farmacéuticamente aceptables.
CO11112331A 2009-03-13 2011-09-01 Sales de adición de trometamina con derivados de ácido azabifenilaminobenzoico como inhibidores de dhodh CO6501157A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09382032A EP2230232A1 (en) 2009-03-13 2009-03-13 Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors

Publications (1)

Publication Number Publication Date
CO6501157A2 true CO6501157A2 (es) 2012-08-15

Family

ID=40671396

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11112331A CO6501157A2 (es) 2009-03-13 2011-09-01 Sales de adición de trometamina con derivados de ácido azabifenilaminobenzoico como inhibidores de dhodh

Country Status (21)

Country Link
US (1) US20120003183A1 (es)
EP (2) EP2230232A1 (es)
JP (1) JP2012520251A (es)
KR (1) KR20110126695A (es)
CN (1) CN102341372A (es)
AR (1) AR075737A1 (es)
AU (1) AU2010223527A1 (es)
CA (1) CA2754785A1 (es)
CL (1) CL2011002213A1 (es)
CO (1) CO6501157A2 (es)
EA (1) EA201101298A1 (es)
EC (1) ECSP11011384A (es)
IL (1) IL214517A0 (es)
MX (1) MX2011009147A (es)
NZ (1) NZ594491A (es)
PE (1) PE20120328A1 (es)
SG (2) SG10201400568PA (es)
TW (1) TW201033177A (es)
UY (1) UY32465A (es)
WO (1) WO2010102825A1 (es)
ZA (1) ZA201105743B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) * 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
CN110903219A (zh) * 2018-09-18 2020-03-24 广东东阳光药业有限公司 酰胺衍生物的盐及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
EP1935416A3 (en) 2001-04-05 2008-10-22 Aventis Pharma Inc (Z) -2-cyano-3-hydroxybut-2-enoic acid (4'-trifluoromethylphenyl) amide for the treatment of multiple sclerosis
WO2002102374A1 (en) * 2001-06-19 2002-12-27 Merck & Co., Inc. Amine salt of an integrin receptor antagonist
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
US7071355B2 (en) 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
AU2003300530A1 (en) 2002-12-23 2004-07-14 4Sc Ag Dhodh-inhibitors and method for their identification
BRPI0511290A (pt) 2004-05-21 2007-12-18 Uab Research Foundation composições e métodos referentes aos inibidores da sìntese da pirimidina
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
CN101043883A (zh) 2004-10-19 2007-09-26 安万特药物公司 (z)－2－氰基－3－羟基－丁－2－烯酸－(4'－三氟甲基苯基)－酰胺用于治疗炎症性肠病的用途
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico

Also Published As

Publication number Publication date
US20120003183A1 (en) 2012-01-05
JP2012520251A (ja) 2012-09-06
NZ594491A (en) 2013-11-29
MX2011009147A (es) 2011-09-15
AU2010223527A1 (en) 2011-08-25
CN102341372A (zh) 2012-02-01
WO2010102825A1 (en) 2010-09-16
EP2230232A1 (en) 2010-09-22
CA2754785A1 (en) 2010-09-16
PE20120328A1 (es) 2012-03-29
TW201033177A (en) 2010-09-16
UY32465A (es) 2010-05-31
SG173824A1 (en) 2011-09-29
ECSP11011384A (es) 2011-11-30
SG10201400568PA (en) 2014-07-30
IL214517A0 (en) 2011-09-27
AR075737A1 (es) 2011-04-20
EP2406222A1 (en) 2012-01-18
ZA201105743B (en) 2012-04-25
CL2011002213A1 (es) 2012-03-09
EA201101298A1 (ru) 2012-04-30
KR20110126695A (ko) 2011-11-23

Similar Documents

Publication Publication Date Title
CO6501157A2 (es) Sales de adición de trometamina con derivados de ácido azabifenilaminobenzoico como inhibidores de dhodh
ECSP12012212A (es) Derivados de ariletinilo
ECSP11011365A (es) Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh
ES2669189T3 (es) Compuestos de carbazol útiles como inhibidores del bromodominio
CY1117481T1 (el) Φαρμακευτικη συνθεση που περιεχει παραγωγο κινολινης
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
AR066107A1 (es) Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen.
AR082112A1 (es) Derivados de imidazopiridina, su procedimiento de preparacion y su aplicacion en terapeutica
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
UY39338A (es) Derivados de piperidinona como inhibidores mdm2, composiciones farmacéuticas que los contienen y sus usos
EA201170096A1 (ru) Замещенные производные пиримидона
ECSP10010337A (es) Derivados de carboxamidas azabicíclicas, su preparación y su aplicación en terapéutica
ECSP066829A (es) 5,6 dialquil-7 -amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos
ECSP10010405A (es) Procesos e intermediarios para la preparacion de derivados de acido 5-bifenil-4-il-2-metilpentanoico
ES2587284T3 (es) 5-Fluoro-pirimidinas 2,4-disustituidas como inhibidores selectivos de CDK9
AR083903A1 (es) Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
MY169179A (en) Novel piperidine compound or salt thereof
AR066605A1 (es) Derivados de heteroarilamida pirimidona
NI200900181A (es) Nuevos compuestos heterocíclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos.
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
ES2570659T3 (es) Agonistas de adenosina A1 para el tratamiento del glaucoma y de la hipertensión ocular
BR112013017416A2 (pt) derivado de indola ou indazola ou sal do mesmo
RS53965B1 (en) ACILBENZENA DERIVATIVES
AR085542A1 (es) Compuestos de azaespirodecanona como inhibidores de hsl

Legal Events

Date Code Title Description
FG Application granted